ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1601

Pilot Testing Supports Utility of a Point-of-Care Dashboard to Enhance Patient and Clinician Partnerships in the Management of RA

Stephanie Mathew1, John Mecchella1, Lisa Johnson2, Aricca Van Citters2, Stacy Courtnay3, Jennifer Marden4, Jabeen Ahmad2, Guy Eakin5, Eugene Nelson2, Salahuddin Kazi6 and Scott Pompa1, 1Dartmouth-Hitchcock Medical Center, Lebanon, NH, 2The Dartmouth Institute for Health Policy & Clinical Practice, Lebanon, NH, 3Patient Partner, Atlanta, GA, 4Dartmouth-Hitchcock Medical Center; Patient Partner, Lebanon, NH, 5Arthritis Foundation, Atlanta, GA, 6Veterans Affairs North Texas Healthcare System / UT Southwestern Medical Center, Dallas, TX

Meeting: ACR Convergence 2020

Keywords: Patient reported outcomes, quality of care, rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 9, 2020

Title: Measures & Measurement of Healthcare Quality Poster

Session Type: Poster Session D

Session Time: 9:00AM-11:00AM

Background/Purpose: Increasing evidence exists that health outcomes are improved when people living with a chronic condition partner with their clinicians to coproduce their care based on their values, preferences, goals, and the best scientific evidence. This partnership may be aided by a data display tool, or dashboard, that presents longitudinal patient-reported outcomes (PROs), clinical data, and medications and is reviewed together to co-assess health status and co-decide next steps in the plan of care. This study assesses the utility of a dashboard to support coproduction of care for adults with RA.

Methods: We pilot tested the rheumatology dashboard with two rheumatologists and their adult RA patients at a rural academic health system. The dashboard resides within the Epic electronic health record and aggregates PROs and clinical data in real-time for review by the patient and clinician together (Figure 1). PRO data include the Routine Assessment of Patient Index Data (RAPID3); and, clinical data include the Clinical Disease Activity Index. RA-specific medications (Biologics, DMARDs, steroids, NSAIDs) map to the dashboard. Consecutive RA patients completed a a 19-item survey following their clinic visit to assess the impact of the dashboard on communication and shared decision making with their clinicians. Data were collected between January and March 2020. Feedback from clinicians was collected during biweekly meetings with the research team.

Results: Nineteen consecutive adult RA patients completed the post-visit survey. Mean (SD) age was 57 (12), 79% were female, 56% had a greater than high school education, and 39% had actively flaring RA (self-assessed). Three-quarters of patients (14 of 19) submitted pre-visit questionnaires (RAPID3) prior to their visit. Of those patients, 74% discussed the RAPID3 results with their clinician, and the clinician shared the dashboard in almost every visit that they discussed the RAPID3 (13 of 14). Two-thirds of patients (9 of 14) felt that the data and information in the dashboard was useful in discussions with their clinicians, helped them talk about what matters most, and helped them work with their clinician to make healthcare decisions. Half (7 of 14) felt that the dashboard helped them create a care plan that they could act on at home. Less than a third (4 of 14) thought that the data and information changed the content or focus of the discussion. Two thirds of patients (9 of 14) would recommend the dashboard to a friend or colleague with RA. Clinicians valued the ability to review and discuss with patients their disease activity over time and the impact of medications on their health status. Limitations included the small sample size as a result of decreased in-clinic visits during the study timeframe due to Covid-19.

Conclusion: Our study demonstrates that the rheumatology dashboard supports in-person review and discussion of PROs and clinical data and facilitates a meaningful dialogue and shared decision making between RA patients and their clinicians. Additional efforts are ongoing to spread the dashboard use to other clinicians in the department and to determine optimal use of the dashboard during telehealth visits.

Figure 1. Rheumatology Dashboard (Epic Electronic Health Record) © 2020 Epic Systems Corporation. Used with Permission.


Disclosure: S. Mathew, None; J. Mecchella, None; L. Johnson, None; A. Van Citters, None; S. Courtnay, None; J. Marden, None; J. Ahmad, None; G. Eakin, None; E. Nelson, None; S. Kazi, ABIM, 1, Regeneron, 1, Sanofi, 1; S. Pompa, None.

To cite this abstract in AMA style:

Mathew S, Mecchella J, Johnson L, Van Citters A, Courtnay S, Marden J, Ahmad J, Eakin G, Nelson E, Kazi S, Pompa S. Pilot Testing Supports Utility of a Point-of-Care Dashboard to Enhance Patient and Clinician Partnerships in the Management of RA [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/pilot-testing-supports-utility-of-a-point-of-care-dashboard-to-enhance-patient-and-clinician-partnerships-in-the-management-of-ra/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/pilot-testing-supports-utility-of-a-point-of-care-dashboard-to-enhance-patient-and-clinician-partnerships-in-the-management-of-ra/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology